Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

mor growth inhibition in models of breast cancer, colorectal cancer, non-small cell lung cancer, and glioblastoma, and has been shown to cause substantial tumor regression in all models tested. Significantly, a single dose of XL880 completely inhibited tumor growth for 21 days in a glioblastoma model.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in Phase II and Phase I clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Sankyo. For more information, please visit the company's web site at www.exelixis.com.

This press release contains forward-looking statements, including without limitation statements related to the potential efficacy of XL880. Words such as "suggest," "believes," "indicates," "should," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the potential failure of XL880 to demonstrate safety and efficacy in clinical testing. These and other risk factors are discussed under "Risk Factors" and elsewhere in Exelixis'
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Capecitabine More Than Doubles Time to Progression and Overall Response ... + Placebo in Patients with 2nd or 3rd Line Metastatic ... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) yesterday announced ... Akt-inhibitor for cancer, in combination with capecitabine as a treatment ...
... , New study finds patients who opt for surgery have decreased ... People with the spine disease called degenerative spondylolisthesis ... from pain over time compared to those who do not have ... of The Journal of Bone and Joint Surgery ...
Cached Medicine Technology:Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 2Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 3Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 4Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 5Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 6Back to Normal: Surgery Improves Outcomes for Spine Patients 2Back to Normal: Surgery Improves Outcomes for Spine Patients 3Back to Normal: Surgery Improves Outcomes for Spine Patients 4
(Date:7/9/2014)... Using an innovative tool that captures heretofore hidden ways ... identified a protein that makes breast cancer cells more ... to trigger cancer,s spread in part by blocking two ... finding that suggests these two disease processes could have ... the July 10 issue of Nature , points ...
(Date:7/9/2014)... findings from Fox Chase Cancer Center paint a relatively ... of breast cancers that have spread to the chest ... that grow into the skin, regardless of size and ... as stage III and called "locally advanced" tumors, ... cancer, often with poor survival. Locally advanced breast cancers ...
(Date:7/9/2014)... -- Researchers from The Miriam Hospital have found ... who are also depressed have difficulty sticking to ... particularly true for women, and screening and brief ... of treatment. The study and its findings are ... , Chronic obstructive pulmonary disease is a ...
(Date:7/9/2014)... July 9, 2014 There has been a sharp ... Southwestern Medical Center using MyChart, the online, interactive service ... communicate with their healthcare providers, schedule appointments, and renew ... patients actively using MyChart each year increased ... increased more than 10-fold, according to a study by ...
(Date:7/9/2014)... Cup highlights, Brian Williams refreshing old school rap classics, ... railings. A University of Colorado Cancer Center study published ... YouTube also allows researchers, journals, and health advocates to ... cancer and prevention. , "No matter what field you,re ... communicate around the world," says Chante Karimkhani, MD candidate ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study of dermatology on YouTube shows new ways science reaches public 2
... 5, 2008/Saranac Lake, N.Y.-- On May 12, 2008, the ... in their Distinguished Americans series. The stamp, the eleventh ... (1848-1915). Stamp collecting is one of the most popular ... 20 million American collectors participating in the activity. The ...
... PRINCETON, N.J., May 7 Patients, nurses,physicians and other ... on the State House May 12 to protest the ... 2009 state budget,plan., WHAT: "Care Today, Gone Tomorrow," ... House steps, West State Street, Trenton, WHEN: 12 ...
... from Caring.com Now Available to Thousands ... of Pennsylvanians Caring for an Aging Parent, ... to,announce a partnership with Trib Total Media, publisher of ... the,magazine,s new online companion. The new online resource,( http://pacaregiver.caring.com ...
... HMS Holdings Corp. (Nasdaq:,HMSY) today announced that it ... which will be held May 13-15, 2008 at the ... CEO, and Walter Hosp, Chief Financial,Officer of HMS Holdings ... PT., HMS Holdings Corp. (Nasdaq: HMSY ) ...
... families in Mexico support innovations to extend the local, productive impact of remittances shines ... ... in Mexico and the US. - Broad, support in communities of origin for ... money from the US. -, Family members in Mexico would encourage senders ...
... leads $12 Million in Series A First Tranche Financing, ... NGN Capital announced,today the formation of ACT Biotech Inc., ... cancer drugs. ACT Biotech has,entered into a license agreement ... early stage oncology assets. In conjunction with the,agreement, ACT ...
Cached Medicine News:Health News:New United States Postal Service stamp honors an American scientist 2Health News:New United States Postal Service stamp honors an American scientist 3Health News:Caring.com Partners With Trib Total Media to Support the Development of a New Online Eldercare Resource 2Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 2Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 3Health News:ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare 2
The Spex SkinSkan is the only in-vivo, fibre-optic spectrofluorometer designed specifically for skin-fluorescence measurements. It is also ideal for many remote sensing steady-state fluorescence appl...
The essence of fluorescence analysis is sensitivity. The high throughput optical system in the RF-5301PC employs a blazed holographic grating, photomultiplier and digital signal processing to provide...
The new Gemini EM microplate spectrofluorometer builds on the successful Gemini platform. This next generation reader incorporates all of the high performance features of the Gemini XS with new capab...
... DNA, RNA, Or Fluorescent Tags. Accurate quantitation of ... to life science research. The RF-Mini 150 Fluorometer ... as small as 1ng/ml of DNA specific Hoechst ... and emission filters, the RF-Mini 150 can measure ...
Medicine Products: